Back to Search Start Over

Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure

Authors :
Yasushi Sakata
Javed Butler
Biykem Bozkurt
G. Michael Felker
Ca Magdy Abdelhamid
Hiroyuki Tsutsui
Stamatis Adamopoulos
James L. Januzzi
Tomohito Ohtani
Gerasimos Filippatos
John R. Teerlink
Randall C. Starling
Mark H. Drazner
Paul A. Heidenreich
Petar M. Seferović
Teruhiko Imamura
Massimo F Piepoli
Marco Metra
Koichiro Kinugawa
Juan Esteban Gomez-Mesa
Ewa A. Jankowska
Shelley Zieroth
Kazuhiro Yamamoto
Prateeti Khazanie
Gregg C. Fonarow
Andrew J.S. Coats
Orly Vardeny
Piotr Ponikowski
Mona Fiuzat
Giuseppe M.C. Rosano
Stefan D. Anker
Clyde W. Yancy
Carolyn S.P. Lam
Yuya Matsue
Michael Böhm
Nancy M. Albert
Jian Zhang
John Atherton
Publication Year :
2021

Abstract

In this document, we propose a universal definition of heart failure (HF) as the following: HF is a clinical syndrome with symptoms and or signs caused by a structural and/or functional cardiac abnormality and corroborated by elevated natriuretic peptide levels and or objective evidence of pulmonary or systemic congestion. We propose revised stages of HF as follows. At-risk for HF (Stage A), for patients at risk for HF but without current or prior symptoms or signs of HF and without structural or biomarkers evidence of heart disease. Pre-HF (stage B), for patients without current or prior symptoms or signs of HF, but evidence of structural heart disease or abnormal cardiac function, or elevated natriuretic peptide levels. HF (Stage C), for patients with current or prior symptoms and/or signs of HF caused by a structural and/or functional cardiac abnormality. Advanced HF (Stage D), for patients with severe symptoms and/or signs of HF at rest, recurrent hospitalizations despite guideline-directed management and therapy (GDMT), refractory or intolerant to GDMT, requiring advanced therapies such as consideration for transplant, mechanical circulatory support, or palliative care. Finally, we propose a new and revised classification of HF according to left ventricular ejection fraction (LVEF). The classification includes HF with reduced EF (HFrEF): HF with an LVEF of ≤40%; HF with mildly reduced EF (HFmrEF): HF with an LVEF of 41% to 49%; HF with preserved EF (HFpEF): HF with an LVEF of ≥50%; and HF with improved EF (HFimpEF): HF with a baseline LVEF of ≤40%, a ≥10-point increase from baseline LVEF, and a second measurement of LVEF of40%.

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....0022169796bca82ac8135924750b0b73